SARS-CoV-2-specific memory B cells can persist in the elderly despite loss of neutralising antibodies

Anna Jeffery-Smith; Alice R Burton; Sabela Lens; Chloe Rees-Spear; Monika Patel; Robin Gopal; Luke Muir; Felicity Aiano; Katie J Doores; J. Yimmy Chow; Shamez N Ladhani; Maria Zambon; Laura E McCoy; Mala K Maini.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-446322

Documentos relacionados

  1. SARS-CoV-2-specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies.
  2. Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children.
  3. One-Year Sustained Cellular and Humoral Immunities in Coronavirus Disease 2019 (COVID-19) Convalescents.
  4. mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants.
  5. The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination.
  6. Distinct Homologous and Variant-Specific Memory B-Cell and Antibody Response Over Time After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccination.
  7. SARS-CoV-2 Omicron BA.1 breakthrough infection drives late remodeling of the memory B cell repertoire in vaccinated individuals.
  8. SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses.
  9. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection.
  10. Plasmablasts in previously immunologically naïve COVID-19 patients express markers indicating mucosal homing and secrete antibodies cross-reacting with SARS-CoV-2 variants and other beta-coronaviruses.